Enliven Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $2.56B
- P/E (TTM)
- –
- Dividend yield
- –
About Enliven Therapeutics
Pharmaceutical Preparations, SIC 2834
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies. The company applies a precision medicine approach rooted in validated biological targets and differentiated chemistry to improve survival outcomes and quality of life for patients. Its primary clinical program centers on ELVN-001, a potent and selective ATP-competitive tyrosine kinase inhibitor targeting the BCR-ABL gene fusion for individuals with chronic myeloid leukemia. In addition to its core oncology program, Enliven engages in research-stage opportunities across other medical areas, including discovery efforts directed toward Graves' disease.
The company operates primarily at a clinical and discovery development stage, conducting clinical trials including the ENABLE Phase 1 study and planned Phase 3 evaluations. It holds global commercial rights to its internal pipeline assets while exploring strategic collaborations and options for programs such as ELVN-002. Enliven's primary operations and corporate headquarters are located in Boulder, Colorado.
Summary of the business section of Enliven Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Enliven Therapeutics, Inc.
- Headquarters
- Burlingame, CA
- Address
- 205 Park Road 94010
- Phone
- (650) 547-5814
- Website
- enliventherapeutics.com
- Employees
- 60, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, San Francisco, California
Stock & identifiers
- Ticker
- ELVN
- Exchange
- Nasdaq
- IPO date
- Mar 12, 2020
- Shares outstanding
- 73M, Jul 28, 2026
- Public float
- $836.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-8.33 reverse, May 11, 2023
- SEC CIK
- 1672619
- CUSIP
- 29337E102
- ISIN
- US29337E1029
- EIN
- 81-1523849
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Richard A. Fair | PRESIDENT AND CEO, Director | – |
| Samuel Kintz | PRESIDENT AND CEO, Director | 890,392 |
| Benjamin Hohl | CHIEF FINANCIAL OFFICER | 38,000 |
| Helen Louise Collins | CHIEF MEDICAL OFFICER | 25,000 |
| Joseph P. Lyssikatos | CHIEF SCIENTIFIC OFFICER | 758,938 |
| Anish Patel | CHIEF OPERATING OFFICER | 235,011 |
| Mika K. Derynck | Director | 87,373 |
| Lori Anne Kunkel | Director | 47,773 |
| Richard A. Heyman | Director | 146,320 |
| Jake Bauer | Director | 87,372 |
| J. Scott Garland | Director | – |
| Rahul D. Ballal | Director | 22,341 |
| Rishi Gupta | Director | 7,663,349 |
| Andrew John Phillips | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Richard Fair | $11.92M | $8.47M | $3.47M | $111 | – |
| FY2025 Sam Kintz | $8.91M | -$3.93M | $3.47M | $111 | – |
| FY2024 Sam Kintz | $5.46M | $11.75M | $2.75M | $163 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 60 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 1, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 1, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Feb 23, 2023 | Name change | Name changed from IMARA Inc. to Enliven Therapeutics, Inc. |
| Nov 10, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 10, 2022 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Oct 7, 2022 | Merger vote | Definitive merger proxy statement |
| Mar 12, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 9, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |